Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PrimXMAD:PRM -0.75%77 EV-to-EBITDA is 6.39 as of Jul. 17, 2026, which is 27% below its 10-year median of 8.73. GuruFocus rates XMAD:PRM with a GF Score™ of 77/100 and a GF Value™ of €7.95 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 511 Medical Devices & Instruments companies, Prim ranks better than 83.76% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Prim's enterprise value is €216.9 Mil.
Prim's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €33.9 Mil. Therefore, Prim's EV-to-EBITDA for today is 6.39.
The historical rank and industry rank for Prim's EV-to-EBITDA or its related term are showing as below:
XMAD:PRM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.42 Med: 8.73 Max: 898.37
Current: 6.39
During the past 13 years, the highest EV-to-EBITDA of Prim was 898.37. The lowest was 5.42. And the median was 8.73.
XMAD:PRM's EV-to-EBITDA is ranked better than 83.76% of 511
companies
in the Medical Devices & Instruments industry
Industry Median: 14.29
vs XMAD:PRM: 6.39
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-07-17), Prim's stock price is €13.20.
Prim's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.980. Therefore, Prim's PE Ratio (TTM) for today is 13.47.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Prim (XMAD:PRM) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Prim's share price for today is €13.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prim's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.980.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Prim's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:PRM vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Prim's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prim EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Prim's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Prim's EV-to-EBITDA falls into.
Prim's current Enterprise Value is €216.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prim's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €33.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prim (XMAD:PRM) has a EV-to-EBITDA of 6.39 as of Jul. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Prim. This is 27% below median its historical median of 8.73. Over the past decade, Prim's EV-to-EBITDA has ranged from 5.42 to 898.37. According to the industry distribution chart, Prim ranks #83 out of 511 companies in the Medical Devices & Instruments industry, placing it in the top 16.2%.
Is Prim's EV-to-EBITDA too high?
Prim's current EV-to-EBITDA of 6.39 is 27% below median its 10-year median of 8.73. Over the past 10 years, this metric has ranged from a low of 5.42 to a high of 898.37. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.29. Prim's value of 6.39 is 55.3% below this industry median. Based on the distribution chart, Prim ranks #83 out of 511 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Prim has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prim's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Prim ranks #83 out of 511 companies for EV-to-EBITDA. This places Prim in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 14.29. Prim's value of 6.39 is 55.3% below this benchmark. Historically, Prim's own EV-to-EBITDA has ranged from 5.42 to 898.37 over the past decade. While the company's 10-year median is 8.73 vs. the industry median of 14.29, Prim has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.29, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prim's current EV-to-EBITDA of 6.39 is 55.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Prim. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prim's current EV-to-EBITDA is 6.39, which is 27% below median its own 10-year median of 8.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prim stock overvalued right now?
Based on GuruFocus' analysis, Prim (XMAD:PRM) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.95, compared to a current price of €13.20 — trading 66% above its estimated fair value. The current EV-to-EBITDA is 6.39, which is 27% below median its 10-year median of 8.73 and 55.3% below the Medical Devices & Instruments industry median of 14.29. Prim's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Prim (XMAD:PRM), the current EV-to-EBITDA is 6.39 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prim (XMAD:PRM) Overvalued in 2026?
Based on GuruFocus' analysis, Prim stock appears to be overvalued.
The current stock price of €13.20 is trading 66% above its estimated GF Value™ of €7.95.
GuruFocus considers Prim to be Significantly Overvalued.
Key valuation signals for XMAD:PRM:
EV-to-EBITDA: 6.39 (27% below median its 10-year median of 8.73)
GF Value™: €7.95 vs. price of €13.20 (66% above fair value)
Industry Position: 55.3% below the Medical Devices & Instruments median (#83 of 511)
No single metric tells the full story. See the XMAD:PRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prim SA is engaged in the provision of hospital supplies. The company is in a hospital and orthopedic supplies and materials for physiotherapy, thalassotherapy, thermal therapy, rehabilitation, geriatrics, as well as daily living aids. Prim work across a division of healthcare units such as Operating Theatres; Pain Management Centres; Plastic Surgery; Endosurgery and Cardiovascular.
77GF Score
Get the complete analysis for XMAD:PRM
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PRM has been successfully added to your 
